Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Atezolizumab (with chemotherapy),"Triple-negative breast cancer (TNBC), advanced or metastatic, PDL1 expression over 1%",Atezolizumab (with chemotherapy) (Tecentriq),Recommended for decline,Hospital,Oncology Agents and Immunosuppressants
